Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 8/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | CTSA | P10619 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16679849 | 0.90 | SMN1; SMN2 (0.44) | FAAHSMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL3663293 | 0.86 | FAAH (0.58) | FAAHSMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL5085127 | 0.85 | CYP26A1 (0.49) | ITGB3ITGA2BFAAHSMN1; SMN2NPC1 | |
| SCHEMBL16680706 | 0.84 | SMN1; SMN2 (0.48) | FAAHSMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL5181827 | 0.84 | KMT2A (0.53) | FAAHSMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL5085765 | 0.83 | SMN1; SMN2 (0.50) | FAAHSMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL5499794 | 0.82 | POLB (0.57) | ITGB3ITGA2BFAAHSMN1; SMN2NPC1 | |
| SCHEMBL5500456 | 0.82 | MMEL1 (0.48) | FAAHSMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL844472 | 0.82 | SMN1; SMN2 (0.57) | FAAHSMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL14040614 | 0.82 | SMN1; SMN2 (0.57) | FAAHSMN1; SMN2NPC1RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452990-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2016-09-27 | — | — | US | disclosed |
| US-20150126492-A1 | Complement Pathway Modulators and Uses Thereof | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126492-A1 | Complement Pathway Modulators and Uses Thereof | CFB, CFH, TFPI | ITGB3 365/4885ITGA2B 101/4885FAAH 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.